A Phase 3 interventional study of atorvastatin in Familial Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 40 sites in 15 countries. Open to participants aged 6 Years to 15 Years. Per ClinicalTrials.gov, last updated 2021-02-21.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Hyperlipoproteinemia Type II with a site in United States — 17 open to participants now, 18 under way, 6 of them phase 3. Hyperlipoproteinemia Type II · United States.
Among the 76 studies in Hyperlipoproteinemia Type II with a site in United States, this one is the 27th largest by enrollment of the 68 interventional ones that give a count, is one of 3 that started in 2009, is one of 30 in phase 3, and was the 18th registered.
249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.
Browse Hyperlipoproteinemia Type II studies →17 of the 76 studies in Hyperlipoproteinemia Type II with a site in United States are open now. Recruiting first, the newest first:
Arrowhead Pharmaceuticals · Sites in United States, Denmark, Poland
Ages 12–17
University of Wisconsin, Madison · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Australia, Belgium and 17 more countries
Ages 6–17
Brigham and Women's Hospital · Sites in United States
Novartis Pharmaceuticals · Sites in United States, Austria, China and 8 more countries
Ages 2–11
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.
This study: 6 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 34 · Phase 4 4
First in 1985; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 272 is above the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.
Median enrollment 163 across the 68 interventional studies, 22 across the 8 observational. Of the 57 that completed or were terminated, 32 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 76 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 2 studies filed under Hyperlipoproteinemia Type II — fewer than ten, so there is no comparison to draw.
6 of the studies in Hyperlipoproteinemia Type II with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05284513Geisinger ClinicCollaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH) | 2027-01 |
| NCT05750667Northwestern UniversityPenn Family Screening for Familial Hypercholesterolemia | 2027-02-28 |
| NCT07919353Northwestern UniversityPenn Family Screening for Familial Hypercholesterolemia (NHLBI R33) Trial 3 | 2027-02-28 |
| NCT06743659Brigham and Women's HospitalComputerized Decision Support for Identification and Management of Familial Hypercholesterolemia | 2027-03-30 |
| NCT06439654Atlantic Health SystemAtlantic Lipid Lowering Treatment Optimization Program | 2027-05-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 76 studies in Hyperlipoproteinemia Type II with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize three year descriptive growth and development (ie, height, weight, body mass index, Tanner Stage) and efficacy of cholesterol reduction in pediatric subjects with Heterozygous Familial Hypercholesterolemia receiving atorvastatin treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Female of who is not using adequate measures or any female who is pregnant or breastfeeding. Any female who becomes pregnant during study participation will be immediately discontinued from treatment and counseled appropriately about the in utero exposure.
Known to HMG-CoA reductase inhibitors
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects will be treated with atorvastatin
Drug: atorvastatin
Atorvastatin tablets or chewable tablets, 5, 10, 20, 40 mg strengths, once daily, for three years (an 80 mg maximum daily dose is delivered by taking two 40 mg strengths, once daily)
Low Density Lipoprotein Cholesterol (LDL-C; Millimoles Per Liter [mMol/L]) During the Study
Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.
Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36 (or early termination [ET])
Percent Change From Baseline in LDL-C
Assessments were performed in the fasting state (minimum 10-hour fast).
Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36 (or ET)
High-Density Lipoprotein Cholesterol (HDL-C; mMol/L) During the Study
Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.
Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Percent Change From Baseline in HDL-C
Assessments were performed in the fasting state (minimum 10-hour fast).
Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Total Cholesterol (mMol/L) During the Study
Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.
Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Percent Change From Baseline in Total Cholesterol
Assessments were performed in the fasting state (minimum 10-hour fast).
Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Trigylcerides (mMol/L) During the Study
Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.
Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Percent Change From Baseline in Trigylcerides
Assessments were performed in the fasting state (minimum 10-hour fast).
Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Very Low-Density Lipoprotein (VLDL; mMol/L) During the Study
Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.
Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Percent Change From Baseline in VLDL
Assessments were performed in the fasting state (minimum 10-hour fast).
Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Apoliprotein A-1 (Apo A-1; Grams Per Liter [g/L]) During the Study
Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.
Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Percent Change From Baseline in Apo A-1
Assessments were performed in the fasting state (minimum 10-hour fast).
Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Apoliprotein B (Apo B; g/L) During the Study
Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.
Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Percent Change From Baseline in Apo B
Assessments were performed in the fasting state (minimum 10-hour fast).
Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Number of Participants With Shift From Baseline in Tanner_Stage by Timepoint and Baseline Tanner_Stage
Tanner_Stage was assessed based on 2 components by gender, pubic hair and breasts for females and pubic hair and genitalia for males. If these values of components were not same, then the Tanner_Stage had the higher value of 2 components for each gender by visit.
Time frame: Baseline, Months 6, 12, 18, 24, 30, and 36/ET
Height (Centimeters [cm]) During the Study: Males
Investigator assessment of height changes during the study. Change from baseline was also determined.
Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Percent Change From Baseline in Height: Males
Investigator assessment of height changes during the study.
Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Height (cm) During the Study: Females
Investigator assessment of height changes during the study. Change from baseline was also determined.
Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Percent Change From Baseline in Height: Females
Investigator assessment of height changes during the study.
Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Weight (Kilograms [kg]) During the Study: Males
Investigator assessment of weight changes during the study. Change from baseline was also determined.
Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Percent Change From Baseline in Weight: Males
Investigator assessment of weight changes during the study.
Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Weight (kg) During the Study: Females
Investigator assessment of weight changes during the study. Change from baseline was also determined.
Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Percent Change From Baseline in Weight: Females
Investigator assessment of weight changes during the study.
Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Body Mass Index (BMI in kg Per Square Meter [kg/m^2]) During the Study: Males
Investigator assessment of BMI changes during the study. Change from baseline was also determined.
Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Percent Change From Baseline in BMI: Males
Investigator assessment of BMI changes during the study.
Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
BMI (kg/m^2) During the Study: Females
Investigator assessment of BMI changes during the study. Change from baseline was also determined.
Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Percent Change From Baseline in BMI: Females
Investigator assessment of BMI changes during the study.
Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Age (Years) During the Study: Males
Investigator assessment of age during the study. Change from baseline was also determined.
Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Percent Change From Baseline in Age: Males
Investigator assessment of age during the study.
Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Age (Years) During the Study: Females
Investigator assessment of age during the study. Change from baseline was also determined.
Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Percent Change From Baseline in Age: Females
Investigator assessment of age during the study.
Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Flow-Mediated Dilatation (FMD) During the Study
Percent (%) FMD was calculated as (hyperemic diameter minus resting diameter) divided by the resting diameter multiplied by 100. Change from baseline was also determined.
Time frame: Baseline, Months 6, 12, 18, 24, 30 and 36/ET
Percent Change From Baseline in FMD
Percent (%) FMD was calculated as (hyperemic diameter minus resting diameter) divided by the resting diameter multiplied by 100.
Time frame: Months 6, 12, 18, 24, 30 and 36/ET
Percentage of Participants With Overall Expected Maturation and Development Consistent With Expectations as Assessed by the Investigator
Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36 (or early termination)
Percentage of Participants by Study Drug Compliance Category
Compliance to study drug was categorized as \<80%, 80% - 120%, and greater than (\>) 120%.
Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30, and 36 (or early termination)
| Milestone | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| Started | 139 | 132 |
| Completed | 112 | 94 |
| Not completed | 27 | 38 |
| Withdrew: Protocol violation | 4 | 3 |
| Withdrew: Lost to follow-up | 3 | 1 |
| Withdrew: Withdrawal by subject | 7 | 6 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Other | 5 | 13 |
| Withdrew: Ldl below 2.59 mmol/l | 4 | 12 |
| Withdrew: Adverse event | 4 | 2 |
Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.
| mMol/L | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| Baseline (n=139,132) | 6.304 ± 1.3130 | 5.921 ± 1.1646 |
| Month 1 (n=131,130) | 4.087 ± 1.0264 | 3.675 ± 0.8749 |
| Change at Month 1 (n=131,130) | -2.214 ± 0.7568 | -2.233 ± 0.8009 |
| Month 2 (n=132,122) | 3.719 ± 0.8346 | 3.437 ± 0.7438 |
| Change at Month 2 (n=132,122) | -2.586 ± 0.9297 | -2.554 ± 0.9155 |
| Month 3 (n=126,117) | 3.503 ± 0.7566 | 3.270 ± 0.6533 |
| Change at Month 3 (n=126,117) | -2.798 ± 1.0251 | -2.795 ± 1.0835 |
| Month 6 (n=127,115) | 3.366 ± 0.5787 | 3.347 ± 0.5953 |
| Change at Month 6 (n=127,115) | -2.968 ± 1.1096 | -2.732 ± 1.0660 |
| Month 12 (n=121,109) | 3.409 ± 0.7395 | 3.196 ± 0.6565 |
| Change at Month 12 (n=121,109) | -2.966 ± 1.0987 | -2.838 ± 1.1450 |
| Month 18 (n=116,101) | 3.309 ± 0.5933 | 3.261 ± 0.5288 |
| Change at Month 18 (n=116,101) | -3.105 ± 1.1558 | -2.835 ± 1.2128 |
| Month 24 (n=111,96) | 3.316 ± 0.6803 | 3.189 ± 0.6537 |
| Change at Month 24 (n=111,96) | -3.088 ± 1.2026 | -2.933 ± 1.2292 |
| Month 30 (n=112,94) | 3.335 ± 0.6490 | 3.142 ± 0.6916 |
| Change at Month 30 (n=112,94) | -3.090 ± 1.2402 | -3.008 ± 1.1489 |
| Month 36/ET (n=123,117) | 3.450 ± 0.7372 | 3.457 ± 0.8808 |
| Change at Month 36/ET (n=123,117) | -2.855 ± 1.2625 | -2.468 ± 1.3270 |
Assessments were performed in the fasting state (minimum 10-hour fast).
| percent change | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| Month 1 (n=131,130) | -34.995 ± 9.7300 | -37.516 ± 10.0245 |
| Month 2 (n=132,122) | -40.371 ± 9.6468 | -41.939 ± 10.4816 |
| Month 3 (n=126,117) | -43.568 ± 10.2149 | -44.887 ± 12.7530 |
| Month 6 (n=127,115) | -45.647 ± 9.6969 | -43.697 ± 11.1836 |
| Month 12 (n=121,109) | -45.530 ± 10.5112 | -45.727 ± 13.5336 |
| Month 18 (n=116,101) | -47.101 ± 10.5592 | -44.818 ± 13.2623 |
| Month 24 (n=111,96) | -46.944 ± 11.9490 | -46.417 ± 13.8658 |
| Month 30 (n=112,94) | -46.631 ± 12.0206 | -47.734 ± 12.6696 |
| Month 36/ET (n=123,117) | -43.785 ± 13.5585 | -39.863 ± 17.5411 |
Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.
| mMol/L | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| Baseline (n=139,132) | 1.349 ± 0.2732 | 1.277 ± 0.2546 |
| Month 1 (n=131,130) | 1.360 ± 0.2717 | 1.292 ± 0.2650 |
| Change at Month 1 (n=131,130) | 0.010 ± 0.1685 | 0.016 ± 0.1740 |
| Month 2 (n=132,122) | 1.364 ± 0.2805 | 1.297 ± 0.2625 |
| Change at Month 2 (n=132,122) | 0.014 ± 0.2238 | 0.025 ± 0.1600 |
| Month 3 (n=126,117) | 1.371 ± 0.2768 | 1.274 ± 0.2606 |
| Change at Month 3 (n=126,117) | 0.015 ± 0.1943 | 0.011 ± 0.1837 |
| Month 6 (n=127,115) | 1.337 ± 0.2834 | 1.268 ± 0.2311 |
| Change at Month 6 (n=127,115) | -0.011 ± 0.1848 | 0.010 ± 0.1833 |
| Month 12 (n=121,109) | 1.328 ± 0.2885 | 1.241 ± 0.2429 |
| Change at Month 12 (n=121,109) | -0.012 ± 0.1945 | -0.023 ± 0.1727 |
| Month 18 (n=116,102) | 1.367 ± 0.3003 | 1.234 ± 0.2349 |
| Change at Month 18 (n=116,102) | 0.024 ± 0.1923 | -0.027 ± 0.1744 |
| Month 24 (n=111,96) | 1.385 ± 0.2729 | 1.266 ± 0.2443 |
| Change at Month 24 (n=111,96) | 0.027 ± 0.2043 | 0.007 ± 0.1910 |
| Month 30 (n=112,94) | 1.380 ± 0.2942 | 1.265 ± 0.2487 |
| Change at Month 30 (n=112,94) | 0.032 ± 0.1997 | 0.006 ± 0.2150 |
| Month 36/ET (n=123,117) | 1.335 ± 0.2918 | 1.278 ± 0.2516 |
| Change at Month 36/ET (n=123,117) | -0.024 ± 0.1949 | 0.005 ± 0.1975 |
Assessments were performed in the fasting state (minimum 10-hour fast).
| percent change | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| Month 1 (n=131,130) | 1.526 ± 12.7845 | 2.192 ± 14.0769 |
| Month 2 (n=132,122) | 2.195 ± 15.6882 | 2.544 ± 12.7802 |
| Month 3 (n=126,117) | 1.929 ± 14.7329 | 1.674 ± 14.9525 |
| Month 6 (n=127,115) | -0.016 ± 14.8853 | 1.877 ± 14.9113 |
| Month 12 (n=121,109) | -0.069 ± 15.2821 | -1.023 ± 14.1983 |
| Month 18 (n=116,102) | 2.472 ± 14.8939 | -1.165 ± 14.3783 |
| Month 24 (n=111,96) | 3.014 ± 14.9559 | 1.737 ± 15.6924 |
| Month 30 (n=112,94) | 3.345 ± 15.5080 | 1.868 ± 17.2633 |
| Month 36/ET (n=123,117) | -1.125 ± 14.7816 | 1.602 ± 15.4895 |
Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.
| mMol/L | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| Baseline (n=139,132) | 8.056 ± 1.3356 | 7.647 ± 1.2250 |
| Month 1 (n=134,131) | 5.785 ± 1.0497 | 5.352 ± 0.9345 |
| Change at Month 1 (n=134,131) | -2.266 ± 0.7957 | -2.297 ± 0.8516 |
| Month 2 (n=132,124) | 5.435 ± 0.8629 | 5.061 ± 0.7865 |
| Change at Month 2 (n=132,124) | -2.620 ± 0.9581 | -2.654 ± 0.9707 |
| Month 3 (n=127,118) | 5.195 ± 0.8000 | 4.883 ± 0.7034 |
| Change at Month 3 (n=127,118) | -2.869 ± 1.0904 | -2.883 ± 1.1363 |
| Month 6 (n=127,115) | 5.019 ± 0.6380 | 4.982 ± 0.6620 |
| Change at Month 6 (n=127,115) | -3.063 ± 1.1687 | -2.809 ± 1.1133 |
| Month 12 (n=121,109) | 5.081 ± 0.7470 | 4.799 ± 0.7176 |
| Change at Month 12 (n=121,109) | -3.040 ± 1.1353 | -2.945 ± 1.2112 |
| Month 18 (n=116,101) | 4.989 ± 0.6512 | 4.845 ± 0.5401 |
| Change at Month 18 (n=116,101) | -3.168 ± 1.1990 | -2.965 ± 1.2667 |
| Month 24 (n=111,96) | 5.032 ± 0.7111 | 4.817 ± 0.7413 |
| Change at Month 24 (n=111,96) | -3.123 ± 1.2039 | -3.009 ± 1.2871 |
| Month 30 (n=112,95) | 5.075 ± 0.6951 | 4.795 ± 0.8256 |
| Change at Month 30 (n=112,95) | -3.096 ± 1.2999 | -3.048 ± 1.2716 |
| Month 36/ET (n=123,117) | 5.134 ± 0.7863 | 5.099 ± 0.9318 |
| Change at Month 36/ET (n=123,117) | -2.923 ± 1.3256 | -2.543 ± 1.3669 |
Assessments were performed in the fasting state (minimum 10-hour fast).
| percent change | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| Month 1 (n=134,131) | -27.879 ± 8.2639 | -29.653 ± 8.5987 |
| Month 2 (n=132,124) | -31.900 ± 8.5025 | -33.726 ± 9.2319 |
| Month 3 (n=127,118) | -34.784 ± 9.4141 | -36.126 ± 11.0136 |
| Month 6 (n=127,115) | -36.889 ± 9.2297 | -35.055 ± 10.0273 |
| Month 12 (n=121,109) | -36.541 ± 9.2486 | -36.943 ± 11.9418 |
| Month 18 (n=116,101) | -37.772 ± 9.7325 | -36.634 ± 11.4572 |
| Month 24 (n=111,96) | -37.287 ± 9.9578 | -37.317 ± 12.2461 |
| Month 30 (n=112,95) | -36.662 ± 11.2064 | -37.856 ± 12.5116 |
| Month 36/ET (n=123,117) | -35.063 ± 12.0345 | -32.013 ± 14.5000 |
Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.
| mMol/L | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| Baseline (n=139,132) | 0.880 ± 0.4343 | 0.980 ± 0.4986 |
| Month 1 (n=134,131) | 0.759 ± 0.3958 | 0.815 ± 0.3848 |
| Change at Month 1 (n=134,131) | -0.121 ± 0.3895 | -0.166 ± 0.5024 |
| Month 2 (n=132,124) | 0.772 ± 0.3837 | 0.741 ± 0.3382 |
| Change at Month 2 (n=132,124) | -0.103 ± 0.3652 | -0.246 ± 0.4825 |
| Month 3 (n=127,118) | 0.699 ± 0.2916 | 0.748 ± 0.3357 |
| Change at Month 3 (n=127,118) | -0.166 ± 0.3937 | -0.237 ± 0.4466 |
| Month 6 (n=127,115) | 0.691 ± 0.3602 | 0.801 ± 0.3848 |
| Change at Month 6 (n=127,115) | -0.183 ± 0.4305 | -0.188 ± 0.4880 |
| Month 12 (n=121,109) | -0.747 ± 0.3901 | 0.789 ± 0.4050 |
| Change at Month 12 (n=121,109) | -0.136 ± 0.4060 | -0.181 ± 0.5255 |
| Month 18 (n=116,102) | 0.687 ± 0.3435 | 0.765 ± 0.3438 |
| Change at Month 18 (n=116,102) | -0.190 ± 0.3665 | -0.219 ± 0.4623 |
| Month 24 (n=111,96) | 0.725 ± 0.3676 | 0.790 ± 0.3651 |
| Change at Month 24 (n=111,96) | -0.133 ± 0.4112 | -0.179 ± 0.4956 |
| Month 30 (n=112,95) | 0.788 ± 0.3454 | 0.781 ± 0.4167 |
| Change at Month 30 (n=112,95) | -0.082 ± 0.3898 | -0.187 ± 0.5728 |
| Month 36/ET (n=123,117) | 0.764 ± 0.4220 | 0.794 ± 0.3894 |
| Change at Month 36/ET (n=123,117) | -0.092 ± 0.4615 | -0.171 ± 0.5216 |
Assessments were performed in the fasting state (minimum 10-hour fast).
| percent change | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| Month 1 (n=134,131) | -5.950 ± 39.0995 | -5.927 ± 51.1811 |
| Month 2 (n=132,124) | -3.260 ± 42.5136 | -14.832 ± 40.4952 |
| Month 3 (n=127,118) | -8.760 ± 41.1184 | -14.415 ± 39.9951 |
| Month 6 (n=127,115) | -11.817 ± 41.9879 | -9.097 ± 43.0350 |
| Month 12 (n=121,109) | -7.981 ± 40.4511 | -7.950 ± 48.7238 |
| Month 18 (n=116,102) | -13.113 ± 39.3990 | -12.443 ± 37.3822 |
| Month 24 (n=111,96) | -6.697 ± 38.7027 | -7.328 ± 45.3694 |
| Month 30 (n=112,95) | 0.657 ± 43.3886 | -4.935 ± 63.1887 |
| Month 36/ET (n=123,117) | -0.703 ± 50.6333 | -7.759 ± 45.6372 |
Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.
| mMol/L | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| Baseline (n=139,132) | 0.403 ± 0.1993 | 0.449 ± 0.2288 |
| Month 1 (n=134,131) | 0.348 ± 0.1823 | 0.374 ± 0.1770 |
| Change at Month 1 (n=134,131) | -0.056 ± 0.1793 | -0.076 ± 0.2307 |
| Month 2 (n=132,124) | 0.354 ± 0.1757 | 0.340 ± 0.1541 |
| Change at Month 2 (n=132,124) | -0.047 ± 0.1672 | -0.113 ± 0.2215 |
| Month 3 (n=127,118) | 0.320 ± 0.1333 | 0.344 ± 0.1548 |
| Change at Month 3 (n=127,118) | -0.076 ± 0.1805 | -0.108 ± 0.2044 |
| Month 6 (n=127,115) | 0.317 ± 0.1652 | 0.367 ± 0.1767 |
| Change at Month 6 (n=127,115) | -0.084 ± 0.1977 | -0.086 ± 0.2240 |
| Month 12 (n=121,109) | 0.343 ± 0.1786 | 0.362 ± 0.1862 |
| Change at Month 12 (n=121,109) | -0.062 ± 0.1872 | -0.082 ± 0.2421 |
| Month 18 (n=116,101) | 0.315 ± 0.1571 | 0.349 ± 0.1571 |
| Change at Month 18 (n=116,101) | -0.087 ± 0.1680 | -0.102 ± 0.2126 |
| Month 24 (n=111,96) | 0.332 ± 0.1680 | 0.363 ± 0.1680 |
| Change at Month 24 (n=111,96) | -0.061 ± 0.1887 | -0.081 ± 0.2285 |
| Month 30 (n=112,95) | 0.361 ± 0.1581 | 0.358 ± 0.1914 |
| Change at Month 30 (n=112,95) | -0.038 ± 0.1781 | -0.086 ± 0.2621 |
| Month 36/ET (n=123,117) | 0.350 ± 0.1930 | 0.364 ± 0.1782 |
| Change at Month 36/ET (n=123,117) | -0.042 ± 0.2112 | -0.079 ± 0.2385 |
Assessments were performed in the fasting state (minimum 10-hour fast).
| percent change | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| Month 1 (n=134,131) | -6.060 ± 39.3300 | -5.805 ± 51.7264 |
| Month 2 (n=132,124) | -3.097 ± 42.3626 | -14.694 ± 40.1710 |
| Month 3 (n=127,118) | -8.711 ± 41.2631 | -14.263 ± 39.7239 |
| Month 6 (n=127,115) | -11.591 ± 42.4219 | -9.158 ± 43.1397 |
| Month 12 (n=121,109) | -7.739 ± 40.7579 | -7.827 ± 48.9819 |
| Month 18 (n=116,101) | -12.911 ± 39.7908 | -12.768 ± 37.4142 |
| Month 24 (n=111,96) | -6.654 ± 38.7945 | -6.920 ± 46.3317 |
| Month 30 (n=112,95) | 0.627 ± 43.6239 | -4.751 ± 64.2502 |
| Month 36/ET (n=123,117) | -0.520 ± 51.3422 | -7.842 ± 45.4640 |
Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.
| g/L | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| Baseline (n=138,132) | 1.396 ± 0.1839 | 1.308 ± 0.2006 |
| Month 1 (n=132,130) | 1.419 ± 0.2233 | 1.337 ± 0.1927 |
| Change at Month 1 (n=132,130) | 0.025 ± 0.1639 | 0.032 ± 0.1506 |
| Month 2 (n=131,123) | 1.411 ± 0.1952 | 1.334 ± 0.1950 |
| Change at Month 2 (n=131,123) | 0.016 ± 0.1519 | 0.025 ± 0.1355 |
| Month 3 (n=126,117) | 1.405 ± 0.1914 | 1.306 ± 0.1919 |
| Change at Month 3 (n=126,117) | 0.005 ± 0.1713 | 0.006 ± 0.1557 |
| Month 6 (n=123,110) | 1.386 ± 0.2081 | 1.329 ± 0.1894 |
| Change at Month 6 (n=123,110) | -0.007 ± 0.1609 | 0.026 ± 0.1818 |
| Month 12 (n=120,108) | 1.347 ± 0.1893 | 1.271 ± 0.1798 |
| Change at Month 12 (n=120,108) | -0.041 ± 0.1574 | -0.028 ± 0.1586 |
| Month 18 (n=114,100) | 1.339 ± 0.1972 | 1.266 ± 0.1676 |
| Change at Month 18 (n=114,100) | -0.049 ± 0.1558 | -0.038 ± 0.1643 |
| Month 24 (n=113,95) | 1.364 ± 0.1929 | 1.275 ± 0.1736 |
| Change at Month 24 (n=113,95) | -0.032 ± 0.1749 | -0.027 ± 0.1799 |
| Month 30 (n=112,95) | 1.357 ± 0.2247 | 1.268 ± 0.1848 |
| Change at Month 30 (n=112,95) | -0.040 ± 0.1857 | -0.036 ± 0.1861 |
| Month 36/ET (n=125,118) | 1.327 ± 0.2081 | 1.272 ± 0.1664 |
| Change at Month 36/ET (n=125,118) | -0.073 ± 0.1725 | -0.040 ± 0.1676 |
Assessments were performed in the fasting state (minimum 10-hour fast).
| percent change | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| Month 1 (n=132,130) | 2.229 ± 12.4001 | 3.301 ± 12.2009 |
| Month 2 (n=131,123) | 1.701 ± 11.0364 | 2.499 ± 10.7656 |
| Month 3 (n=126,117) | 1.041 ± 12.4204 | 1.192 ± 12.1640 |
| Month 6 (n=123,110) | -0.069 ± 12.1109 | 3.011 ± 14.1347 |
| Month 12 (n=120,108) | -2.365 ± 11.5882 | -1.370 ± 12.3901 |
| Month 18 (n=114,100) | -3.042 ± 11.2219 | -1.980 ± 12.2170 |
| Month 24 (n=113,95) | -1.611 ± 12.4618 | -0.961 ± 13.9868 |
| Month 30 (n=112,95) | -2.342 ± 13.3357 | -1.695 ± 14.2732 |
| Month 36/ET (n=125,118) | -4.804 ± 12.0443 | -1.954 ± 12.7229 |
Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.
| g/L | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| Baseline (n=138,132) | 1.454 ± 0.2890 | 1.381 ± 0.2619 |
| Month 1 (n=132,130) | 1.062 ± 0.2423 | 0.967 ± 0.2257 |
| Change at Month 1 (n=132,130) | -0.395 ± 0.1599 | -0.415 ± 0.1691 |
| Month 2 (n=131,123) | 0.980 ± 0.1929 | 0.916 ± 0.1813 |
| Change at Month 2 (n=131,123) | -0.471 ± 0.1825 | -0.484 ± 0.1858 |
| Month 3 (n=126,117) | 0.930 ± 0.1836 | 0.890 ± 0.1707 |
| Change at Month 3 (n=126,117) | -0.522 ± 0.2152 | -0.518 ± 0.2184 |
| Month 6 (n=123,110) | 0.919 ± 0.1557 | 0.910 ± 0.1683 |
| Change at Month 6 (n=123,110) | -0.535 ± 0.2092 | -0.503 ± 0.2086 |
| Month 12 (n=120,108) | 0.918 ± 0.1816 | 0.871 ± 0.1493 |
| Change at Month 12 (n=120,108) | -0.548 ± 0.2131 | -0.530 ± 0.2194 |
| Month 18 (n=114,100) | 0.893 ± 0.1546 | 0.882 ± 0.1293 |
| Change at Month 18 (n=114,100) | -0.578 ± 0.2343 | -0.533 ± 0.2463 |
| Month 24 (n=113,95) | 0.918 ± 0.1719 | 0.884 ± 0.1575 |
| Change at Month 24 (n=113,95) | -0.551 ± 0.2353 | -0.535 ± 0.2344 |
| Month 30 (n=112,95) | 0.910 ± 0.1723 | 0.885 ± 0.1717 |
| Change at Month 30 (n=112,95) | -0.560 ± 0.2664 | -0.533 ± 0.2467 |
| Month 36/ET (n=125,118) | 0.926 ± 0.1860 | 0.924 ± 0.2173 |
| Change at Month 36/ET (n=125,118) | -0.520 ± 0.2730 | -0.450 ± 0.2748 |
Assessments were performed in the fasting state (minimum 10-hour fast).
| percent change | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| Month 1 (n=132,130) | -26.933 ± 9.5550 | -29.851 ± 10.3544 |
| Month 2 (n=131,123) | -31.867 ± 9.2821 | -33.959 ± 9.9478 |
| Month 3 (n=126,117) | -35.163 ± 10.5680 | -35.849 ± 11.6832 |
| Month 6 (n=123,110) | -35.900 ± 9.3398 | -34.740 ± 10.7982 |
| Month 12 (n=120,108) | -36.624 ± 9.7413 | -36.842 ± 11.6106 |
| Month 18 (n=114,100) | -38.158 ± 10.4084 | -36.211 ± 12.7805 |
| Month 24 (n=113,95) | -36.426 ± 11.4333 | -36.677 ± 12.1824 |
| Month 30 (n=112,95) | -36.668 ± 12.8783 | -36.453 ± 13.6888 |
| Month 36/ET (n=125,118) | -34.507 ± 14.0740 | -31.362 ± 16.4770 |
Tanner_Stage was assessed based on 2 components by gender, pubic hair and breasts for females and pubic hair and genitalia for males. If these values of components were not same, then the Tanner_Stage had the higher value of 2 components for each gender by visit.
| participants | Atorvastatin (5-80 mg): Baseline Tanner_Stage 1 | Atorvastatin (10-80 mg): Baseline Tanner_Stage 2 | Atorvastatin (10-80 mg): Baseline Tanner_Stage 3 | Atorvastatin (10-80 mg): Baseline Tanner_Stage 4 | Atorvastatin (10-80 mg): Baseline Tanner_Stage 5 |
|---|---|---|---|---|---|
| Tanner_Stage 1, Month 6 (n=126,48,25,27,15) | 107 | 0 | 0 | 0 | 0 |
| Tanner_Stage 2 , Month 6 (n=126,48,25,27,15) | 14 | 34 | 0 | 0 | 0 |
| Tanner_Stage 3, Month 6 (n=126,48,25,27,15) | 5 | 10 | 14 | 0 | 0 |
| Tanner_Stage 4, Month 6 (n=126,48,25,27,15) | 0 | 4 | 11 | 25 | 1 |
| Tanner_Stage 5, Month 6 (n=126,48,25,27,15) | 0 | 0 | 0 | 2 | 14 |
| Tanner_Stage 1, Month 12 (n=121,43,23,26,15) | 85 | 0 | 0 | 0 | 0 |
| Tanner_Stage 2, Month 12 (n=121,43,23,26,15) | 25 | 17 | 0 | 0 | 0 |
| Tanner_Stage 3, Month 12 (n=121,43,23,26,15) | 10 | 21 | 11 | 0 | 0 |
| Tanner_Stage 4, Month 12 (n=121,43,23,26,15) | 1 | 5 | 10 | 22 | 1 |
| Tanner_Stage 5, Month 12 (n=121,43,23,26,15) | 0 | 0 | 2 | 4 | 14 |
| Tanner_Stage 1, Month 18 (n=115,41, 21,25,14) | 63 | 0 | 0 | 0 | 0 |
| Tanner_Stage 2, Month 18 (n=115,41, 21,25,14) | 31 | 15 | 0 | 0 | 0 |
| Tanner_Stage 3, Month 18 (n=115,41, 21,25,14) | 18 | 16 | 6 | 0 | 0 |
| Tanner_Stage 4, Month 18 (n=115,41, 21,25,14) | 3 | 9 | 11 | 18 | 1 |
| Tanner_Stage 5, Month 18 (n=115,41, 21,25,14) | 0 | 1 | 4 | 7 | 13 |
| Tanner_Stage 1, Month 24 (n=113,38,19,22,14) | 51 | 0 | 0 | 0 | 0 |
| Tanner_Stage 2, Month 24 (n=113,38,19,22,14) | 33 | 9 | 0 | 0 | 0 |
| Tanner_Stage 3, Month 24 (n=113,38,19,22,14) | 20 | 14 | 2 | 0 | 0 |
| Tanner_Stage 4, Month 24 (n=113,38,19,22,14) | 9 | 12 | 13 | 13 | 1 |
| Tanner_Stage 5, Month 24 (n=113,38,19,22,14) | 0 | 3 | 4 | 9 | 13 |
| Tanner_Stage 1, Month 30 (n=111,38,19,23,14) | 39 | 0 | 0 | 0 | 0 |
| Tanner_Stage 2, Month 30 (n=111,38,19,23,14) | 32 | 3 | 0 | 0 | 0 |
| Tanner_Stage 3, Month 30 (n=111,38,19,23,14) | 26 | 11 | 1 | 0 | 0 |
| Tanner_Stage 4, Month 30 (n=111,38,19,23,14) | 14 | 18 | 9 | 11 | 1 |
| Tanner_Stage 5, Month 30 (n=111,38,19,23,14) | 0 | 6 | 9 | 12 | 13 |
| Tanner_Stage 1, Month 36/ET (n=127,52,25,31,18) | 41 | 0 | 0 | 0 | 0 |
| Tanner_Stage 2, Month 36/ET (n=127,52,25,31,18) | 31 | 6 | 0 | 0 | 0 |
| Tanner_Stage 3, Month 36/ET (n=127,52,25,31,18) | 25 | 10 | 2 | 0 | 0 |
| Tanner_Stage 4, Month 36/ET (n=127,52,25,31,18) | 25 | 24 | 13 | 12 | 0 |
| Tanner_Stage 5, Month 36/ET (n=127,52,25,31,18) | 5 | 12 | 10 | 19 | 18 |
Investigator assessment of height changes during the study. Change from baseline was also determined.
| cm | Atorvastatin (5-80 mg) |
|---|---|
| Baseline (n=146) | 144.36 ± 16.004 |
| Month 1 (n=141) | 145.21 ± 16.114 |
| Change at Month 1 (n=141) | 0.68 ± 0.964 |
| Month 2 (n=138) | 145.93 ± 16.302 |
| Change at Month 2 (n=138) | 1.27 ± 0.964 |
| Month 3 (n=133) | 146.00 ± 16.139 |
| Change at Month 3 (n=133) | 1.72 ± 1.172 |
| Month 6 (n=129) | 147.17 ± 16.033 |
| Change at Month 6 (n=129) | 3.24 ± 1.485 |
| Month 12 (n=123) | 150.75 ± 16.321 |
| Change at Month 12 (n=123) | 6.67 ± 2.385 |
| Month 18 (n=119) | 153.26 ± 16.388 |
| Change at Month 18 (n=119) | 9.31 ± 2.978 |
| Month 24 (n=114) | 156.03 ± 16.001 |
| Change at Month 24 (n=114) | 12.11 ± 3.630 |
| Month 30 (n=114) | 158.78 ± 15.770 |
| Change at Month 30 (n=114) | 14.86 ± 4.403 |
| Month 36/ET (n=134) | 160.59 ± 15.602 |
| Change at Month 36/ET (n=134) | 15.53 ± 6.801 |
Investigator assessment of height changes during the study.
| percent change | Atorvastatin (5-80 mg) |
|---|---|
| Month 1 (n=141) | 0.47 ± 0.689 |
| Month 2 (n=138) | 0.88 ± 0.652 |
| Month 3 (n=133) | 1.19 ± 0.777 |
| Month 6 (n=129) | 2.25 ± 0.987 |
| Month 12 (n=123) | 4.66 ± 1.606 |
| Month 18 (n=119) | 6.53 ± 2.021 |
| Month 24 (n=114) | 8.53 ± 2.607 |
| Month 30 (n=114) | 10.49 ± 3.260 |
| Month 36/ET (n=134) | 10.97 ± 5.010 |
Investigator assessment of height changes during the study. Change from baseline was also determined.
| cm | Atorvastatin (5-80 mg) |
|---|---|
| Baseline (n=125) | 145.28 ± 14.108 |
| Month 1 (n=124) | 146.06 ± 14.045 |
| Change at Month 1 (n=124) | 0.71 ± 1.378 |
| Month 2 (n=119) | 146.57 ± 13.919 |
| Change at Month 2 (n=119) | 1.19 ± 1.700 |
| Month 3 (n=115) | 146.81 ± 13.838 |
| Change at Month 3 (n=115) | 1.68 ± 1.278 |
| Month 6 (n=113) | 147.87 ± 13.619 |
| Change at Month 6 (n=113) | 2.77 ± 1.720 |
| Month 12 (n=107) | 150.84 ± 12.968 |
| Change at Month 12 (n=107) | 5.50 ± 2.992 |
| Month 18 (n=99) | 152.77 ± 12.648 |
| Change at Month 18 (n=99) | 7.41 ± 4.043 |
| Month 24 (n=95) | 154.79 ± 11.913 |
| Change at Month 24 (n=95) | 9.61 ± 5.120 |
| Month 30 (n=93) | 156.43 ± 11.288 |
| Change at Month 30 (n=93) | 11.23 ± 6.118 |
| Month 36/ET (n=121) | 156.52 ± 11.032 |
| Change at Month 36/ET (n=121) | 11.23 ± 7.551 |
Investigator assessment of height changes during the study.
| percent change | Atorvastatin (5-80 mg) |
|---|---|
| Month 1 (n=124) | 0.51 ± 1.004 |
| Month 2 (n=119) | 0.84 ± 1.220 |
| Month 3 (n=115) | 1.20 ± 0.925 |
| Month 6 (n=113) | 1.98 ± 1.291 |
| Month 12 (n=107) | 3.93 ± 2.262 |
| Month 18 (n=99) | 5.30 ± 3.036 |
| Month 24 (n=95) | 6.93 ± 3.933 |
| Month 30 (n=93) | 8.13 ± 4.740 |
| Month 36/ET (n=121) | 8.14 ± 5.789 |
Investigator assessment of weight changes during the study. Change from baseline was also determined.
| kg | Atorvastatin (5-80 mg) |
|---|---|
| Baseline (n=146) | 40.79 ± 14.079 |
| Month 1 (n=141) | 41.18 ± 14.287 |
| Change at Month 1 (n=141) | 0.36 ± 1.203 |
| Month 2 (n=138) | 41.83 ± 14.467 |
| Change at Month 2 (n=138) | 0.80 ± 1.422 |
| Month 3 (n=133) | 41.68 ± 14.266 |
| Change at Month 3 (n=133) | 1.08 ± 1.907 |
| Month 6 (n=129) | 42.47 ± 14.564 |
| Change at Month 6 (n=129) | 2.00 ± 2.528 |
| Month 12 (n=123) | 45.29 ± 15.526 |
| Change at Month 12 (n=123) | 4.65 ± 3.822 |
| Month 18 (n=119) | 47.53 ± 16.164 |
| Change at Month 18 (n=119) | 7.02 ± 4.432 |
| Month 24 (n=114) | 49.77 ± 16.401 |
| Change at Month 24 (n=114) | 9.27 ± 5.079 |
| Month 30 (n=114) | 52.12 ± 17.100 |
| Change at Month 30 (n=114) | 11.61 ± 6.032 |
| Month 36/ET (n=134) | 53.50 ± 16.787 |
| Change at Month 36/ET (n=134) | 12.35 ± 6.771 |
Investigator assessment of weight changes during the study.
| percent change | Atorvastatin (5-80 mg) |
|---|---|
| Month 1 (n=141) | 0.94 ± 2.739 |
| Month 2 (n=138) | 2.04 ± 3.262 |
| Month 3 (n=133) | 2.73 ± 4.317 |
| Month 6 (n=129) | 5.09 ± 5.559 |
| Month 12 (n=123) | 11.85 ± 8.172 |
| Month 18 (n=119) | 18.03 ± 9.629 |
| Month 24 (n=114) | 24.28 ± 11.696 |
| Month 30 (n=114) | 30.46 ± 14.058 |
| Month 36/ET (n=134) | 32.54 ± 17.409 |
Investigator assessment of weight changes during the study. Change from baseline was also determined.
| kg | Atorvastatin (5-80 mg) |
|---|---|
| Baseline (n=125) | 42.14 ± 14.038 |
| Month 1 (n=125) | 42.50 ± 14.007 |
| Change at Month 1 (n=125) | 0.36 ± 0.924 |
| Month 2 (n=120) | 42.86 ± 14.209 |
| Change at Month 2 (n=120) | 0.67 ± 1.338 |
| Month 3 (n=115) | 43.34 ± 14.753 |
| Change at Month 3 (n=115) | 1.24 ± 1.819 |
| Month 6 (n=113) | 44.26 ± 15.027 |
| Change at Month 6 (n=113) | 2.10 ± 2.409 |
| Month 12 (n=107) | 46.61 ± 15.158 |
| Change at Month 12 (n=107) | 4.41 ± 3.317 |
| Month 18 (n=99) | 48.32 ± 14.670 |
| Change at Month 18 (n=99) | 6.24 ± 4.291 |
| Month 24 (n=95) | 50.13 ± 14.731 |
| Change at Month 24 (n=95) | 8.55 ± 5.038 |
| Month 30 (n=93) | 51.73 ± 14.681 |
| Change at Month 30 (n=93) | 10.02 ± 6.127 |
| Month 36/ET (n=121) | 51.55 ± 14.498 |
| Change at Month 36/ET (n=121) | 9.77 ± 7.047 |
Investigator assessment of weight changes during the study.
| percent change | Atorvastatin (5-80 mg) |
|---|---|
| Month 1 (n=125) | 0.97 ± 2.303 |
| Month 2 (n=120) | 1.85 ± 3.206 |
| Month 3 (n=115) | 3.16 ± 4.149 |
| Month 6 (n=113) | 5.37 ± 5.529 |
| Month 12 (n=107) | 11.65 ± 8.391 |
| Month 18 (n=99) | 16.79 ± 11.315 |
| Month 24 (n=95) | 23.43 ± 14.333 |
| Month 30 (n=93) | 27.83 ± 17.507 |
| Month 36/ET (n=121) | 27.26 ± 21.389 |
Investigator assessment of BMI changes during the study. Change from baseline was also determined.
| kg/m^2 | Atorvastatin (5-80 mg) |
|---|---|
| Baseline (n=146) | 18.97 ± 3.664 |
| Month 1 (n=141) | 18.94 ± 3.751 |
| Change at Month 1 (n=141) | 0.01 ± 0.577 |
| Month 2 (n=138) | 19.06 ± 3.755 |
| Change at Month 2 (n=138) | 0.06 ± 0.658 |
| Month 3 (n=133) | 18.99 ± 3.745 |
| Change at Month 3 (n=133) | 0.07 ± 0.890 |
| Month 6 (n=129) | 19.04 ± 3.881 |
| Change at Month 6 (n=129) | 0.10 ± 1.218 |
| Month 12 (n=123) | 19.34 ± 3.922 |
| Change at Month 12 (n=123) | 0.37 ± 1.541 |
| Month 18 (n=119) | 19.65 ± 4.053 |
| Change at Month 18 (n=119) | 0.73 ± 1.625 |
| Month 24 (n=114) | 19.91 ± 4.098 |
| Change at Month 24 (n=114) | 0.99 ± 1.745 |
| Month 30 (n=114) | 20.18 ± 4.400 |
| Change at Month 30 (n=114) | 1.25 ± 2.099 |
| Month 36/ET (n=134) | 20.28 ± 4.137 |
| Change at Month 36/ET (n=134) | 1.33 ± 1.958 |
Investigator assessment of BMI changes during the study.
| percent change | Atorvastatin (5-80 mg) |
|---|---|
| Month 1 (n=141) | 0.03 ± 2.953 |
| Month 2 (n=138) | 0.31 ± 3.405 |
| Month 3 (n=133) | 0.39 ± 4.496 |
| Month 6 (n=129) | 0.55 ± 5.673 |
| Month 12 (n=123) | 2.10 ± 7.065 |
| Month 18 (n=119) | 3.98 ± 7.533 |
| Month 24 (n=114) | 5.45 ± 8.306 |
| Month 30 (n=114) | 6.80 ± 9.737 |
| Month 36/ET (n=134) | 7.31 ± 9.290 |
Investigator assessment of BMI changes during the study. Change from baseline was also determined.
| kg/m^2 | Atorvastatin (5-80 mg) |
|---|---|
| Baseline (n=125) | 19.44 ± 3.994 |
| Month 1 (n=124) | 19.45 ± 3.973 |
| Change at Month 1 (n=124) | -0.02 ± 0.582 |
| Month 2 (n=119) | 19.47 ± 3.940 |
| Change at Month 2 (n=119) | 0.00 ± 0.756 |
| Month 3 (n=115) | 19.54 ± 4.171 |
| Change at Month 3 (n=115) | 0.13 ± 0.861 |
| Month 6 (n=113) | 19.68 ± 4.288 |
| Change at Month 6 (n=113) | 0.24 ± 1.004 |
| Month 12 (n=107) | 19.98 ± 4.257 |
| Change at Month 12 (n=107) | 0.60 ± 1.305 |
| Month 18 (n=99) | 20.24 ± 3.990 |
| Change at Month 18 (n=99) | 0.92 ± 1.432 |
| Month 24 (n=95) | 20.50 ± 3.976 |
| Change at Month 24 (n=95) | 1.38 ± 1.624 |
| Month 30 (n=93) | 20.75 ± 4.014 |
| Change at Month 30 (n=93) | 1.59 ± 1.931 |
| Month 36/ET (n=121) | 20.71 ± 4.217 |
| Change at Month 36/ET (n=121) | 1.46 ± 1.948 |
Investigator assessment of BMI changes during the study.
| percent change | Atorvastatin (5-80 mg) |
|---|---|
| Month 1 (n=124) | -0.06 ± 3.058 |
| Month 2 (n=119) | 0.16 ± 3.777 |
| Month 3 (n=115) | 0.73 ± 4.314 |
| Month 6 (n=113) | 1.26 ± 4.992 |
| Month 12 (n=107) | 3.33 ± 6.765 |
| Month 18 (n=99) | 5.14 ± 7.578 |
| Month 24 (n=95) | 7.68 ± 8.661 |
| Month 30 (n=93) | 8.89 ± 9.916 |
| Month 36/ET (n=121) | 8.06 ± 10.147 |
Investigator assessment of age during the study. Change from baseline was also determined.
| years | Atorvastatin (5-80 mg) |
|---|---|
| Baseline (n=146) | 9.94 ± 2.489 |
| Month 1 (n=141) | 10.05 ± 2.553 |
| Change at Month 1 (n=141) | 0.11 ± 0.309 |
| Month 2 (n=138) | 10.14 ± 2.583 |
| Change at Month 2 (n=138) | 0.18 ± 0.387 |
| Month 3 (n=133) | 10.21 ± 2.567 |
| Change at Month 3 (n=133) | 0.29 ± 0.457 |
| Month 6 (n=129) | 10.43 ± 2.552 |
| Change at Month 6 (n=129) | 0.55 ± 0.499 |
| Month 12 (n=123) | 10.96 ± 2.543 |
| Change at Month 12 (n=123) | 1.02 ± 0.155 |
| Month 18 (n=119) | 11.47 ± 2.544 |
| Change at Month 18 (n=119) | 1.54 ± 0.501 |
| Month 24 (n=114) | 11.93 ± 2.534 |
| Change at Month 24 (n=114) | 2.02 ± 0.132 |
| Month 30 (n=114) | 12.46 ± 2.553 |
| Change at Month 30 (n=114) | 2.54 ± 0.500 |
| Month 36/ET (n=134) | 12.69 ± 2.587 |
| Change at Month 36/ET (n=134) | 2.67 ± 0.899 |
Investigator assessment of age during the study.
| percent change | Atorvastatin (5-80 mg) |
|---|---|
| Month 1 (n=141) | 1.09 ± 3.327 |
| Month 2 (n=138) | 1.86 ± 4.184 |
| Month 3 (n=133) | 3.16 ± 5.175 |
| Month 6 (n=129) | 6.06 ± 5.956 |
| Month 12 (n=123) | 11.13 ± 3.878 |
| Month 18 (n=119) | 16.82 ± 7.732 |
| Month 24 (n=114) | 21.92 ± 6.623 |
| Month 30 (n=114) | 27.67 ± 9.855 |
| Month 36/ET (n=134) | 28.90 ± 13.486 |
Investigator assessment of age during the study. Change from baseline was also determined.
| years | Atorvastatin (5-80 mg) |
|---|---|
| Baseline (n=125) | 10.55 ± 2.421 |
| Month 1 (n=125) | 10.66 ± 2.436 |
| Change at Month 1 (n=125) | 0.11 ± 0.317 |
| Month 2 (n=120) | 10.78 ± 2.430 |
| Change at Month 2 (n=120) | 0.20 ± 0.402 |
| Month 3 (n=115) | 10.75 ± 2.449 |
| Change at Month 3 (n=115) | 0.28 ± 0.450 |
| Month 6 (n=113) | 10.99 ± 2.477 |
| Change at Month 6 (n=113) | 0.52 ± 0.502 |
| Month 12 (n=107) | 11.50 ± 2.416 |
| Change at Month 12 (n=107) | 0.99 ± 0.097 |
| Month 18 (n=99) | 12.02 ± 2.503 |
| Change at Month 18 (n=99) | 1.52 ± 0.502 |
| Month 24 (n=95) | 12.42 ± 2.482 |
| Change at Month 24 (n=95) | 1.98 ± 0.144 |
| Month 30 (n=93) | 12.99 ± 2.564 |
| Change at Month 30 (n=93) | 2.52 ± 0.502 |
| Month 36/ET (n=121) | 13.07 ± 2.547 |
| Change at Month 36/ET (n=121) | 2.54 ± 0.940 |
Investigator assessment of age during the study.
| percent change | Atorvastatin (5-80 mg) |
|---|---|
| Month 1 (n=125) | 1.10 ± 3.169 |
| Month 2 (n=120) | 2.00 ± 4.128 |
| Month 3 (n=115) | 2.74 ± 4.549 |
| Month 6 (n=113) | 5.18 ± 5.221 |
| Month 12 (n=107) | 10.00 ± 2.811 |
| Month 18 (n=99) | 15.20 ± 6.006 |
| Month 24 (n=95) | 20.08 ± 5.298 |
| Month 30 (n=93) | 25.35 ± 7.415 |
| Month 36/ET (n=121) | 25.73 ± 12.168 |
| percentage of participants | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| Baseline (n=139,132) | 99.3 | 100.0 |
| Month 1 (n=118,113) | 100.0 | 100.0 |
| Month 2 (n=116,109) | 100.0 | 100.0 |
| Month 3 (n=130,118) | 100.0 | 100.0 |
| Month 6 (n=127,115) | 100.0 | 99.1 |
| Month 12 (n=121,109) | 100.0 | 99.1 |
| Month 18 (n=115,102) | 100.0 | 100.0 |
| Month 24 (n=113,95) | 100.0 | 100.0 |
| Month 30 (n=111,94) | 100.0 | 98.9 |
| Month 36/Early Termination (n=128,127) | 99.2 | 99.2 |
Percent (%) FMD was calculated as (hyperemic diameter minus resting diameter) divided by the resting diameter multiplied by 100. Change from baseline was also determined.
| % FMD | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| Baseline (n=37,36) | 5.523 ± 3.2062 | 6.651 ± 4.4926 |
| Month 6 (n=27,23) | 5.749 ± 2.5047 | 6.520 ± 4.0763 |
| Change at Month 6 (n=27,23) | -0.063 ± 3.4768 | -0.759 ± 4.8732 |
| Month 12 (n=32,29) | 4.732 ± 1.8477 | 6.363 ± 8.0370 |
| Change at Month 12 (n=32,29) | -0.952 ± 3.6796 | -0.778 ± 9.4743 |
| Month 18 (n=33,28) | 4.942 ± 2.6740 | 4.668 ± 3.8874 |
| Change at Month 18 (n=33,28) | -0.762 ± 3.7374 | -2.556 ± 6.3123 |
| Month 24 (n=33,28) | 4.538 ± 2.4239 | 5.679 ± 4.3224 |
| Change at Month 24 (n=33,28) | -1.166 ± 3.2524 | -1.545 ± 7.2325 |
| Month 30 (n=33,28) | 5.571 ± 2.7198 | 5.191 ± 2.5120 |
| Change at Month 30 (n=33,28) | -0.134 ± 3.3399 | -2.033 ± 5.8591 |
| Month 36/ET (n=34,33) | 4.987 ± 2.2540 | 5.360 ± 2.9873 |
| Change at Month 36/ET (n=34,33) | -0.550 ± 3.6625 | -1.563 ± 4.8355 |
Percent (%) FMD was calculated as (hyperemic diameter minus resting diameter) divided by the resting diameter multiplied by 100.
| percent change | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| Month 6 (n=27,23) | 14.867 ± 67.6028 | -0.205 ± 60.7192 |
| Month 12 (n=32,29) | -3.880 ± 56.1910 | 15.444 ± 207.6932 |
| Month 18 (n=33,28) | -4.598 ± 68.0267 | -24.387 ± 81.5683 |
| Month 24 (n=33,28) | -9.992 ± 57.3868 | 3.850 ± 102.2001 |
| Month 30 (n=33,28) | 7.000 ± 63.0894 | -18.804 ± 42.2259 |
| Month 36/ET (n=34,33) | 0.648 ± 62.5814 | -7.506 ± 61.2361 |
Compliance to study drug was categorized as \<80%, 80% - 120%, and greater than (\>) 120%.
| percentage of participants | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| Month 1, <80% (n=135,132) | 3.0 | 6.8 |
| Month 1, 80%-120% (n=135,132) | 97.0 | 93.2 |
| Month 1, >120% (n=135,132) | 0 | 0 |
| Month 2, <80% (n=132,126) | 6.8 | 7.9 |
| Month 2, 80%-120% (n=132,126) | 92.4 | 92.1 |
| Month 2, >120% (n=132,126) | 0.8 | 0 |
| Month 3, <80% (n=130,118) | 3.8 | 7.6 |
| Month 3, 80%-120% (n=130,118) | 95.4 | 92.4 |
| Month 3, >120% (n=130,118) | 0.8 | 0 |
| Month 6, <80% (n=127,115) | 7.9 | 9.6 |
| Month 6, 80%-120% (n=127,115) | 92.1 | 90.4 |
| Month 6, >120% (n=127,115) | 0 | 0 |
| Month 12, <80% (n=121,109) | 7.4 | 7.3 |
| Month 12, 80%-120% (n=121,109) | 92.6 | 92.7 |
| Month 12, >120% (n=121,109) | 0 | 0 |
| Month 18, <80% (n=116,102) | 4.3 | 5.9 |
| Month 18, 80%-120% (n=116,102) | 94.0 | 94.1 |
| Month 18, >120% (n=116,102) | 1.7 | 0 |
| Month 24, <80% (n=113,95) | 8.8 | 9.5 |
| Month 24, 80%-120% (n=113,95) | 91.2 | 89.5 |
| Month 24, >120% (n=113,95) | 0 | 1.1 |
| Month 30, <80% (n=112,94) | 8.0 | 6.4 |
| Month 30, 80%-120% (n=112,94) | 92.0 | 92.6 |
| Month 30, >120% (n=112,94) | 0 | 1.1 |
| Month 36/ET, <80% (n=129,129) | 11.6 | 16.3 |
| Month 36/ET, 80%-120% (n=129,129) | 86.8 | 83.7 |
| Month 36/ET, >120% (n=129,129) | 1.6 | 0 |
Collected over Baseline up through Month 36. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atorvastatin (5-80 mg): Tanner_Stage 1 | — | 14/139 (10.1%) | 93/139 (66.9%) |
| Atorvastatin (10-80 mg): Tanner_Stage 2+ | — | 7/132 (5.3%) | 86/132 (65.2%) |
| Event | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| AppendicitisInfections and infestations | 2/139 | 0/132 |
| Abdominal painGastrointestinal disorders | 1/139 | 1/132 |
| VomitingGastrointestinal disorders | 0/139 | 1/132 |
| Limb injuryInjury, poisoning and procedural complications | 0/139 | 1/132 |
| Lumbar vertebral fractureInjury, poisoning and procedural complications | 0/139 | 1/132 |
| Thoracic vertebral fractureInjury, poisoning and procedural complications | 0/139 | 1/132 |
| ObesityMetabolism and nutrition disorders | 0/139 | 1/132 |
| Type I diabetes mellitusMetabolism and nutrition disorders | 0/139 | 1/132 |
| SyncopeNervous system disorders | 1/139 | 1/132 |
| Suicide attemptPsychiatric disorders | 0/139 | 1/132 |
| Event | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ |
|---|---|---|
| NasopharyngitisInfections and infestations | 26/139 | 26/132 |
| HeadacheNervous system disorders | 25/139 | 25/132 |
| Abdominal painGastrointestinal disorders | 21/139 | 10/132 |
| Upper respiratory tract infectionInfections and infestations | 20/139 | 10/132 |
| GastroenteritisInfections and infestations | 17/139 | 12/132 |
| VomitingGastrointestinal disorders | 15/139 | 7/132 |
| PyrexiaGeneral disorders | 15/139 | 13/132 |
| InfluenzaInfections and infestations | 13/139 | 14/132 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 14/139 | 5/132 |
| CoughRespiratory, thoracic and mediastinal disorders | 14/139 | 11/132 |
Full Analysis Set (FAS): all participants who took at least one dose of study drug.
| Age, Continuous(years) | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ | Total |
|---|---|---|---|
| Mean | 8.5 ± 1.86 | 12.0 ± 1.68 | 10.2 ± 2.48 |
| Sex: Female, Male(Participants) | Atorvastatin (5-80 mg): Tanner_Stage 1 | Atorvastatin (10-80 mg): Tanner_Stage 2+ | Total |
|---|---|---|---|
| Female | 46 | 79 | 125 |
| Male | 93 | 53 | 146 |
The record gives a start of Mar 2009, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atorvastatin
Hyperlipoproteinemia Type II →
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →